Results 171 to 180 of about 56,943 (309)
Molecular Oncology, EarlyView.RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner +14 more
wiley +1 more source
Productivity and R&D at the Firm Level in French Manufacturing [PDF]
In a companion study to that of Griliches and Mairesse for the United States, we have investigated the relationship between output, labor, and physical and R&D capital during the 1972-1977 period for a sample of 182 R&D performing firms in the French ...
Philippe Cuneo, Jacques Mairesse
core
Quantifying public and private investment in biopharmaceutical R&D: a study of seven middle- and high-income countries. [PDF]
J Pharm Policy PractFowler A +6 more
europepmc +1 more source
Molecular Oncology, EarlyView.CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak +10 more
wiley +1 more source
R&D and productivity in the Indian pharmaceutical firms
Recent researches for developing countries suggest knowledge generating activates is no silver bullet for productivity growth. In this context, this paper examines the impact of R&D activities on firms’ performance for the Indian pharmaceutical industry ...
Sharma, Chandan
core
Do Business Cycles Influence Long-Run Growth? The Effect of Aggregate Demand on Firm-Financed R&D Expenditures [PDF]
This paper finds that inventive activity, as measured by firm-financed R&D expenditures, is procyclical. In addition, the "lost" R&D during recessions is larger than the "extra" R&D during expansions so the overall effect of the business cycle is to ...
Matthew Rafferty
core
Catastrophic health care expenditure among older people with non-communicable diseases in 11 European Union Member States. [PDF]
PLoS OneKutluer S, Pavlova M, Groot W.
europepmc +1 more source
Molecular Oncology, EarlyView.Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
An Extended Accelerator Model of R&D and Physical Investment [PDF]
Using a multivariate autoregressive framework, we have found a simple causal structure for the variables of interest q, s, r, and i, which is consistent with our data.
Jacques Mairesse, Alan K. Siu
core
Economic impact of heart failure in Brazil. [PDF]
J Glob HealthVolpi E Silva N +6 more
europepmc +1 more source